Ellen R. Gaynor, MD

Ellen R. Gaynor, MD

Medicine

Hematology/Oncology
Professor

Languages Spoken

English

Clinical Expertise

  • Bladder Cancer
  • Breast Cancer
  • General Oncology
  • Testicular Cancer
  • prostate Cancer

About Dr. Gaynor

Interests
History, Family and Friends

Medical Education

Medical School
University of Wisconsin Medical School
Residency
Loyola University Medical Center - Internal Medicine: General
Fellowship
  • Loyola University Medical Center - Internal Medicine: Medical Oncology
  • University of Chicago Hospitals and Clinics - Internal Medicine: Hematology & Medical Oncology

Board Certification

American Board of Internal Medicine Subspecialty Hematology
American Board of Internal Medicine Subspecialty Medical Oncology

Research

  • Concurrent chemotherapy is associated with improved survival in elderly patients with bladder cancer undergoing radiotherapy Korpics, M. C.; Block, A. M.; Martin, B.; Hentz, C.; Gaynor, E. R.; Henry, E.; Harkenrider, M. M.; Solanki, A. A., Cancer
  • Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection. Lo, S. S.; Mumby, P. B.; Norton, J.; Rychlik, K.; Smerage, J.; Kash, J.; Chew, H. K.; Gaynor, E. R.; Hayes, D. F.; Epstein, A.; Albain, K. S., Journal of Clinical Oncology
  • A phase II pilot study of high-dose 24-hour continuous infusion of 5-FU and leucovorin and low-dose PALA for patients with colorectal cancer: a Southwest Oncology Group study Whitehead, R. P.; Benedetti, J. K.; Abbruzzese, J. L.; Ardalan, B.; Williamson, S.; Gaynor, E. R.; Balcerzak, S. P.; Macdonald, J. S., Investigational new drugs
View All ResearchShow Less
  • Octreotide for refractory diarrhea associated with capecitabine Tanvetyanon, T.; Gaynor, E. R., Journal of Pharmacy Technology
  • A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911 Press, O. W.; Unger, J. M.; Braziel, R. M.; Maloney, D. G.; Miller, T. P.; LeBlanc, M.; Gaynor, E. R.; Rivkin, S. E.; Fisher, R. I., Blood
  • Dose-intense chemotherapy every 2 weeks with dose-intense cyclophosphamide doxorubicin, vincristine, and prednisone may improve survival in intermediate- and high-grade lymphoma: a phase II study of the Southwest Oncology Group (SWOG 9349), Blayney, D. W.; LeBlanc, M. L.; Grogan, T.; Gaynor, E. R.; Chapman, R. A.; Spiridonidis, C. H.; Taylor, S. A.; Bearman, S. I.; Miller, T. P.; Fisher, R. I.; Southwest Oncology Group, Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • Health status and quality of life in patients with early-stage Hodgkin's disease treated on Southwest Oncology Group Study 9133 Ganz, P. A.; Moinpour, C. M.; Pauler, D. K.; Kornblith, A. B.; Gaynor, E. R.; Balcerzak, S. P.; Gatti, G. S.; Erba, H. P.; McCoy, S.; Press, O. W.; Fisher, R. I., Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • Infusional CHOP chemotherapy (CVAD) with or without chemosensitizers offers no advantage over standard CHOP therapy in the treatment of lymphoma: a Southwest Oncology Group Study Gaynor, E. R.; Unger, J. M.; Miller, T. P.; Grogan, T. M.; White, L. A., Jr; Mills, G. M.; Balcerzak, S. P.; Varterasian, M.; LeBlanc, M.; Fisher, R. I., Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • Phase III randomized intergroup trial of subtotal lymphoid irradiation versus doxorubicin vinblastine, and subtotal lymphoid irradiation for stage IA to IIA Hodgkin's disease, Press, O. W.; LeBlanc, M.; Lichter, A. S.; Grogan, T. M.; Unger, J. M.; Wasserman, T. H.; Gaynor, E. R.; Peterson, B. A.; Miller, T. P.; Fisher, R. I., Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • Interferon alpha consolidation after intensive chemotherapy does not prolong the progression-free survival of patients with low-grade non-Hodgkin's lymphoma: results of the Southwest Oncology Group randomized phase III study 8809 Fisher, R. I.; Dana, B. W.; LeBlanc, M.; Kjeldsberg, C.; Forman, J. D.; Unger, J. M.; Balcerzak, S. P.; Gaynor, E. R.; Roy, V.; Miller, T., Journal of clinical oncology : official journal of the American Society of Clinical Oncology